Akari Therapeutics Announces R&D Day on April 24, 2017
March 17 2017 - 7:00AM
Akari Therapeutics (NASDAQ:AKTX), an emerging growth,
clinical-stage biopharmaceutical company, announced today that it
will hold a Research and Development Day on April 24, 2017 in New
York. The event will be hosted by members of Akari’s executive
leadership team and will feature presentations from investigators
and independent scientific advisors. The meeting will cover three
main areas:
- Interim results from the ongoing phase 2 trial in paroxysmal
nocturnal hemoglobinuria (PNH) will be presented by Dr Anita Hill,
the lead investigator in the study. Dr Hill is a Consultant
Haematologist and Honorary Clinical Associate Professor at Leeds
Teaching Hospital, which is one of the world’s largest treatment
centers for PNH patients.
- Results from the pre-clinical development program targeting new
disease opportunities for our lead compound Coversin, focusing on
its unique dual leukotriene B4 (LTB4)/C5 activity will be presented
by Dr Robert Snelgrove, National Heart and Lung Institute, Imperial
College London whose particular expertise lies in LTB4 and lung
inflammation.
- New data on the pre-clinical pipeline, including the
once-weekly subcutaneous formulation of Coversin, will be presented
by Professor Arne Skerra, Professor of Biological Chemistry at the
University of Munich and Chairman of XL-protein GmbH.
The presentation will be webcast simultaneously.
Details of how to access the presentation and simultaneous webcast
will be posted on the calendar section of the Company’s website
(www.akaritx.com) a week before R&D Day.
About Akari Therapeutics Plc
Akari is a clinical-stage biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics to treat orphan autoimmune and inflammatory diseases.
Akari’s lead drug, Coversin is a second-generation complement
inhibitor that acts on complement component-C5, preventing release
of C5a and formation of C5b-9 (also known as the membrane attack
complex or MAC). C5 inhibition is growing in importance in a range
of rare autoimmune diseases related to dysregulation of the
complement component of the immune system, including Paroxysmal
Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome
(aHUS), and Guillain Barré syndrome (GBS).
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control. Such risks and uncertainties for our company
include, but are not limited to: an inability or delay in obtaining
required regulatory approvals for Coversin and any other product
candidates, which may result in unexpected cost expenditures; risks
inherent in drug development in general; uncertainties in obtaining
successful clinical results for Coversin and any other product
candidates and unexpected costs that may result therefrom; failure
to realize any value of Coversin and any other product candidates
developed and being developed in light of inherent risks and
difficulties involved in successfully bringing product candidates
to market; inability to develop new product candidates and support
existing product candidates; the approval by the FDA and EMA and
any other similar foreign regulatory authorities of other competing
or superior products brought to market; risks resulting from
unforeseen side effects; risk that the market for Coversin may not
be as large as expected; inability to obtain, maintain and enforce
patents and other intellectual property rights or the unexpected
costs associated with such enforcement or litigation; inability to
obtain and maintain commercial manufacturing arrangements with
third party manufacturers or establish commercial scale
manufacturing capabilities; the inability to timely source adequate
supply of our active pharmaceutical ingredients from third party
manufacturers on whom the company depends; our inability to obtain
additional capital on acceptable terms, or at all; unexpected cost
increases and pricing pressures; uncertainties of cash flows and
inability to meet working capital needs; and risks and other risk
factors detailed in our public filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K filed
on March 23, 2016. Except as otherwise noted, these forward-looking
statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements
to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
Contact:
Investor Contact:
The Trout Group
Lee Stern
lstern@troutgroup.com
646–378–2922
Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024